KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Asset Writedowns and Impairment (2023 - 2025)

Historic Asset Writedowns and Impairment for Supernus Pharmaceuticals (SUPN) over the last 3 years, with Q3 2025 value amounting to -$239000.0.

  • Supernus Pharmaceuticals' Asset Writedowns and Impairment fell 72413.79% to -$239000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year decrease of 6334.43%. This contributed to the annual value of $8.9 million for FY2024, which is 5591.66% down from last year.
  • Supernus Pharmaceuticals' Asset Writedowns and Impairment amounted to -$239000.0 in Q3 2025, which was down 72413.79% from $920000.0 recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Asset Writedowns and Impairment high stood at $20.2 million for Q4 2023, and its period low was -$239000.0 during Q3 2025.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $825000.0 (2024), whereas its average is $3.8 million.
  • Examining YoY changes over the last 5 years, Supernus Pharmaceuticals' Asset Writedowns and Impairment showed a top increase of 2506.85% in 2025 and a maximum decrease of 72413.79% in 2025.
  • Quarter analysis of 3 years shows Supernus Pharmaceuticals' Asset Writedowns and Impairment stood at $20.2 million in 2023, then tumbled by 65.81% to $6.9 million in 2024, then tumbled by 103.46% to -$239000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at -$239000.0 for Q3 2025, versus $920000.0 for Q2 2025 and $547000.0 for Q1 2025.